healthcare ltd.

November 11, 2023

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Investor Presentation

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited are submitting herewith enclosed the Investor Presentation in respect of Unaudited Financial Results for the quarter ended September 30, 2023.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

ASHVIN BHAGAVANBHAI VARIYA
Digitally signed by ASHVIN BHAGAVANBHAI VARIYA
Date: 2023.11.11 17:33:41 +05'30'

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: a/a

Registered Office:
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

davaindia®
GENERIC PHARMACY
INDIA'S LARGEST PRIVATE GENERIC PHARMACY RETAIL CHAIN

zota®
healthcare ltd.

NOVEMBER 2023

Zota Health Care Limited

Q2FY24

Performance Highlight

davaindia GENERIC PHARMACY

Safe **Harbour**

This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company . No offering of securities shall be made except by means of offer documents .

This presentation has been prepared on the basis of information and data available with the Company consider reliable. This presentation may not contain all the information that you may consider material. Any liability in respect of the content of or any omission from this presentation is expressly excluded.

Stakeholders are advice to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on website of NSE.

This presentation contains “forward looking statement”, including “future oriented financial information” and “financial outlook”. This forward looking statement is based on management’s current expectations and belief, and subject to uncertainty. Actual result may be vary from the material facts contained in this presentation due to changes in government policies, regulations, economics reforms, natural calamities, competition, technology, etc. Company is not under obligation to inform any update or alter in forward looking statement, whether as a result of any new information or future events.

davaindia GENERIC PHARMACY

Davaindia is **REVOLUTIONISING THE INDIAN HEALTHCARE SCENARIO**

5967 Lakhs
Gross Merchandise Value in H1FY24

58%
Gross Margin in COCO format

702
Fast growing FOFO & COCO store network

30-90%
Savings to consumers on Generic medicines

10.7 Mn+
Happy Consumers

25-30%
Mature COCO Stores EBITDA

We are eliminating the **traditional pharma supply chain and passing benefits to the Consumers**

Sourcing directly from manufacturers and selling directly to consumers…



On an average **~75% savings on medicines as compared to branded counter parts**



Zota Health Care **Business Verticals**

1 DAVAINDIA

- *A Retail generic pharmacy chain which provides quality generic medicines.*
- *Focuses only on private-label products in:*
  - *Medicinal*
  - *OTC*
  - *Ayurvedic*
  - *Cosmetic and Nutraceutical*
- *Key emphasis is on chronic therapies and ailments*
- *One-of-its-kind concept started with 3 pilot stores in 2017*
- *FOFO Stores are operated on an asset-light franchisee model*

02
Store variants Company Owned Company Operated (COCO) and Franchisee Owned Franchisee Operated (FOFO)

30% – 90%
Savings on medicines as compared to branded counterparts

Larger Store Network
125 COCO stores
577 FOFO stores

100%
private labelled products

2 DOMESTIC MARKETING BUSINESS

- *Procures finished dosage forms from domestic formulations manufactures and market them under their portfolio of brands*
- *Markets the products across the country to the distributors, which, in turn, caters to retail pharmacies in their respective districts*

1,050+
Distributors currently present across India

4,000+
Products covering major therapeutic segments

WHO
Partners with WHO recognized manufacturers

3 EXPORTS

- *Commenced operations in 2010 in manufacturing unit in Sachin, SEZ*
- *Manufactures about 250 formulations in the unit*
- *To focus on more and more products registrations in all these countries & company itself holding all the MAs / Registration of all other countries*

284
Product approvals out of 586 dossiers applications

30+
Countries' approval mainly in the semi regulated and regulated markets

Growth led by exclusive foreign distribution network and exclusive MA holding

Davaindia Competitive Edge

davaindia GENERIC PHARMACY

The USP of the brand ranges from quality to affordability to variety to efficiency in operations . . .

BENEFITS TO THE CUSTOMERS

Medicines priced at **low MRP** thereby ensuring affordability by the masses

Private labels offered, helps in building customer trust by ensuring consistency

Continuously adding to its **product range** thereby offering variety

Products procured from **WHO & GMP** approved plants and quality attested at NABL approved labs

BENEFITS TO THE FRANCHISEES

Store operations and the supply chain efficiently managed by cloud based software & AI

Widespread marketing activities helping in promoting the brand and improving sales

Elimination of distributors will ensure timely supply of stock

Franchise will get **1 km radius** ensuring exclusivity

KPI's - **Davaindia**





Note – The Company did a one-time closure of under-performing FOFO stores in Q3FY23, leading to a decrease in total store count.

KPI's - **Davaindia**

davaindia GENERIC PHARMACY

Quarterly GMV
(₹ Lakhs)



Avg. Wallet Spend
(₹)



Davaindia - **COCO Stores**

davaindia©
GENERIC PHARMACY

COCO Monthly Performance Updates

Store Count & GMV of COCO Stores



COCO Monthly Performance Updates

davaindia GENERIC PHARMACY

Average monthly GMV per COCO Store
(₹ Lakhs)



Footfall at COCO Stores
(Thousands)



COCO Stores



States	No. of Stores
Uttar Pradesh	28
Gujarat	22
Haryana	8
Karnataka	1
Madhya Pradesh	3
Delhi	29
Rajasthan	7
Maharashtra	26
Odisha	1
Total	**125**

125

Operational COCO stores
as on 30.09.2023

Operated by wholly-owned subsidiary
Davaindia Health Mart Limited

davaindia- **FOFO Stores**

davaindia GENERIC PHARMACY

davaindia GENERIC PHARMACY

Store Opening Plan **FOFO**



577

Operational FOFO stores as on 30.09.2023

Franchise Owned Franchise Operated (FOFO) Stores

States	No. of Stores
Uttar Pradesh	115
West Bengal	49
Bihar	18
Odisha	71
Telangana	2
Gujarat	46
Haryana	38
Karnataka	4
Madhya Pradesh	58
Kerala	14
Delhi	31
Rajasthan	23
Tamil Nadu	13
Punjab	8
Assam	9
Jharkhand	5
Maharashtra	46
Tripura	7
Goa	1
Himachal Pradesh	2
Chattisgarh	1
Uttarakhand	5
Arunachal Pradesh	4
Jammu & Kashmir	6
Andhra Pradesh	1
Total	**577**

Domestic Operations

Domestic marketing has been the oldest business vertical for the Company and has remained its mainstay in the past. Until 2017, this vertical contributed most of the Company's revenues. This business vertical directly distributes generic drugs, OTC products, and other pharmaceutical products through the Company's distribution network spread across India.

1,050+ Distributors spread across India	4,000+ Products in the portfolio

MARKETING VALUE CHAIN

FDF Manufacturers
WHO-GMP certified manufacturing partners

Branding
Quality check, packaging and
branding under the umbrella of Zota brands

Distribution
Direct distribution to 1,050+ distributors spread across the country

Retail Pharmacies
Ethical marketing, sales distribution and promotional activities undertaken by distributors

Export Operations

Our Exports business vertical, which started in 2010, serves clients in over 30 countries, mainly in the CIS, Latin America, Africa, and Asia. At its plant in Sachin, SEZ, the Company manufactures generic formulations for the dossiers it has registered in foreign markets.
At present, the Company has registered over 284 dossiers, while another 302 dossiers have been filed and are awaiting approval from the relevant regulatory agencies.

250+ Products manufactured	284 Dossiers registered	302 Dossiers pending approval

COUNTRIES EXPORTED TO –

1. Benin
2. Bolivia
3. Cambodia
4. Cameroon
5. Costa Rica
6. Ethiopia
7. Georgia
8. Ivory coast
9. Kenya
10. Mali
11. Myanmar
12. Nepal
13. Nigeria
14. South Africa
15. Sri Lanka
16. Swaziland
17. Tanzania
18. Turkmenistan
19. Uganda
20. Ukraine
21. Uzbekistan
22. Vietnam
23. Zambia
24. Kyrgyzstan
25. Libya
26. Yemen

Supply **Chain Management**

- The Company has outsourced supply chain management to a third-party warehousing & logistics partner.
- A state-of-art central warehousing & processing center has been built in Surat, in Phase 1.
- Eventually the Company will replicate such infrastructure across different zones in the country.

Click the link below for more details

Click here

Q4FY23

Results Highlights

Stand Quarterly **Financial Highlights**

Q-o-Q

Revenues (₹ Lakhs)



Gross Profit (%)



Operating Profit (₹ Lakhs)



PAT (₹ Lakhs)



Y-o-Y

Revenues (₹ Lakhs)



Gross Profit (%)



Operating Profit (₹ Lakhs)



PAT (₹ Lakhs)



Revenue Break up- **Quarterly**

Q2-FY24

4,115



Q1-FY24

3,526



Q2-FY23

3,857



Domestic Sales
Dava India Sales
Export Sales (SEZ)

Stand Profit & Loss Statement- **Quarterly**

Particulars (Rs Lakhs)	Q2FY24	Q1FY24	YoY %	QoQ %	Q2FY23
Export Sales (SEZ)	709.3	369.5	-22%	92%	903.91
Dava India Sales	1915.1	1805.1	57%	6%	1217.00
Domestic Sales	1490.6	1350.5	-14%	10%	1736.35
Revenues from Operations	**4,115.01**	**3,525.07**	**7%**	**17%**	**3,857.26**
Cost of Goods Sold	2,550.91	2,375.00	5%	7%	2,425.27
Gross Profit	**1564.10**	**1150.07**	9%	36%	**1431.99**
% Margin	**38.01%**	**32.63%**	**89 BPS**	**538 BPS**	**37.12%**
Operational Exp	1254.26	1088.54	38%	15%	909.37
Employee cost	478.27	377.55	92%	27%	249.40
Other expenses	775.99	710.99	18%	9%	659.97
Operating Profit	**309.84**	**61.53**	-41%	404%	**522.62**
% Margin	**7.53%**	**1.75%**	**-602 BPS**	**578 BPS**	**13.55%**
Other Income	62.51	35.55	-36%	76%	98.43
EBITDA	**372.35**	**97.08**	-40%	284%	**621.05**
% Margin	**9.05%**	**2.75%**	**-705 BPS**	**629 BPS**	**16.10%**
Depreciation	76.68	55.08	34%	39%	57.36
EBIT	**295.67**	**42.00**	-48%	604%	**563.69**
% Margin	**7.19%**	**1.19%**	**-743 BPS**	**599 BPS**	**14.61%**
Interest Cost	24.96	4.67	864%	434%	2.59
EBT	**270.71**	**37.33**	-52%	625%	**561.10**
% Margin	**6.58%**	**1.06%**	**-797 BPS**	**552 BPS**	**14.55%**
Taxes	59.04	69.79	-57%	-15%	138.72
Profit After Taxes	**178.76**	**21.22**	-58%	742%	**422.40**
% Margin	**4.34%**	**0.60%**	**-661 BPS**	**374 BPS**	**10.95%**

Management **Commentary**

1 DOMESTIC OPERATIONS

*Domestic Revenues **increased** by **7.93% QoQ and a growth of 15.32% YoY at ₹ 3405.73 Lakhs in Q2FY24** supported by healthy performance on both fronts.*

EBITDA at ₹ **179.78** Lakhs for Q2FY24, increased by 84.97% QoQ on account of higher revenue from Davaindia.

2 EXPORTS

*Exports revenues **increased by 91.97% on QoQ basis and decreased 21.53% YoY at ₹ 709.27 Lakhs** in Q2FY24.*

EBITDA at ₹ **192.57 Lakhs** for Q2FY24, increased by 1891.06% on QoQ basis due to high export sales realization.

**Here, Domestic Operations includes the operations of Davaindia.*

Management **Commentary**

"The Company has reported a healthy performance in Q2FY24. Despite challenges on the export front, the Company managed to report a 16% YoY topline growth. Davaindia's business vertical demonstrated robust topline growth of 57% YoY, driven by the expansion of store count, increased average wallet spends, and, consequently, GMV. The domestic business has shown recovery QoQ with a 10% growth; however, it is still 14% lower YoY given the current domestic pharmaceutical industry scenario.

The Company has been aggressively investing in store roll-out, adding over 100 stores in the last two quarters. As of September, the Company has more than 700 operational stores. Subsequently, quarterly footfalls and average wallet spending have also been on a rising trend.

At COCO stores front, the Company is looking for aggressively expansion; as at the date of this presentation 150+ COCO stores are under pipeline and the same are expected to be open shortly.

Profit & Loss **Statement**

Particulars (INR Lakhs)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23
Income from Operations	**5,646.3**	**6,473.3**	**7,158.0**	**7,785.2**	**8,562.9**	**9,511.3**	**10,684.12**	**13,153.33**	**13,836.60**
Other Income	1.4	7.7	5.6	151.9	154.5	151.3	125.66	164.56	255.87
Total Income	**5,647.8**	**6,481.0**	**7,163.6**	**7,937.0**	**8,717.4**	**9,662.6**	**10,809.78**	**13,317.89**	**14,092.47**
Operating Expenses	4,796.5	5,516.8	6,153.8	6,695.0	7,788.7	9,059.7	10,490.90	11,618.38	13,035.65
EBITDA	**851.3**	**964.2**	**1,009.8**	**1,242.0**	**928.7**	**602.9**	**193.22**	**1,699.51**	**1,056.82**
Margin %	**15.1**	**14.9**	**14.1**	**16.0**	**10.8**	**6.3**	**1.8**	**12.9**	**7.6**
Depreciation	150.6	123.5	105.4	93.7	139.4	209.8	316.68	273.05	241.99
EBIT	**700.7**	**840.8**	**904.4**	**1,148.3**	**789.3**	**393.1**	**-123.46**	**1,426.46**	**814.83**
Margin %	**12.4**	**13.0**	**12.6**	**14.8**	**9.2**	**4.1**	**-1.2**	**10.8**	**5.9**
Financial Charges	66.5	68.3	68.2	12.1	3.7	6.9	10.97	7.32	6.33
PBT	**634.2**	**772.4**	**836.2**	**1,136.2**	**785.6**	**386.2**	**-134.43**	**1,419.14**	**808.50**
Margin %	**11.2**	**11.9**	**11.7**	**14.6**	**9.2**	**4.1**	**-1.3**	**10.8**	**5.8**
Tax	207.6	261.5	282.1	407.4	230.7	112.0	-15.3	376.56	206.43
PAT	**426.7**	**510.9**	**554.1**	**726.8**	**554.8**	**274.1**	**-16.24**	**1,058.01**	**659.35**
Margin %	**7.6**	**7.9**	**7.7**	**9.3**	**6.5**	**2.9**	**-0.2**	**8.0**	**4.8**
EPS	**3.0**	**3.6**	**3.9**	**4.2**	**2.3**	**1.1**	**-0.07**	**4.25**	**2.62**

Balance Sheet & **Key Ratios**

Particulars (INR Lakhs)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23
Share capital	1,436.3	1,436.3	1,436.3	1,754.3	1,754.3	2,456.0	2456.03	2,516.0	2,516.0
Reserves and Surplus	395.7	707.8	1,262.0	5,223.4	5,138.2	4,426.9	4,181.2	6,621.4	6,930.3
Non-current liabilities	548.7	272.7	466.8	64.7	87.1	105.3	94.5	102.9	93.8
Current liabilities	1,657.6	1,988.3	2,215.4	2,137.0	1,981.0	1,859.6	1,820.0	3,287.63	2,923.57
Total Equity and Liabilities	**4,038.4**	**4,405.2**	**5,380.5**	**9,179.4**	**8,960.7**	**8,847.9**	**8,551.6**	**9,137.45**	**9,446.31**
Non-current assets	842.4	855.6	932.5	3,605.4	2,723.3	2,961.4	2438.13	5,007.36	3,683.91
Current assets	3,196.0	3,549.5	4,447.9	5,574.1	6,237.4	5,886.4	6,113.5	7,520.57	8,779.80
Total Assets	**4,038.4**	**4,405.2**	**5,380.5**	**9,179.4**	**8,960.7**	**8,847.8**	**8,551.6**	**12,527.93**	**12,463.71**

Key Ratios	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23
RoCE (%)	20.0	23.5	19.3	10.5	8.0	4.0	-1.8	15.4	8.5
RoE (%)	23.3	23.8	20.5	10.4	8.0	4.0	-0.2	11.6	7.0
Net debt to equity (x)	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Interest coverage (x)	10.5	12.3	13.3	94.8	214.5	56.6	-11.3	194.9	128.7
Inventory days	113.9	92.1	121.9	113.8	138.6	97.2	96.1	77.6	94.5
Receivables days	75.6	89.0	87.1	107.5	94.2	111.8	98.5	106.3	*114.9
Payable days	116.2	126.5	148.4	117.8	103.5	82.5	77.6	76.4	102.7

*Receivable days increased due to outstanding of M/s Davaindia Health Mart Lts, Wholly Owned Subsidiary of the Company

Thank You

Contact Information

Mr. Himanshu Zota / Mr. Ashvin Variya

"ZOTA HOUSE", 2/896, Hira Modi Street,
Sagrampura, Surat-395 002 (Gujarat)

cszota@zotahealthcare.com
www.zotahealthcare.com

zota®
healthcare ltd.